FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2991865732> ?p ?o ?g. }

• W2991865732 abstract "Background: The combination of cediranib (ced) and olaparib (olap) improves progression-free survival and overall response rates (ORR) in women with recurrent plat sensitive high-grade serous (HGS) ovarian cancer compared to olap alone. In this Phase 2 study of ced/olap in women with relapsed ovarian cancer (NCT02345265), we observed an ORR of 74% with ced/olap in plat sensitive relapsed patients (pts) and an ORR of 20% in plat resistant pts. BROCA-HR was performed to characterize tumor HRD status and to correlate this with the activity of ced/olap in the plat sensitive and resistant settings. Methods: Pts with relapsed ovarian cancer across 11 centers were enrolled to 2 cohorts, either plat sensitive or resistant. All pts received ced 30mg daily and olap tablets 200mg BID. Archival, pre-treatment, and on-treatment biopsies were collected on all pts where safely feasible; pts also had the option of undergoing a post-progression biopsy. A baseline blood sample was collected for germline testing and matched control. Available samples were sequenced with BROCA-HR, and HRD status was determined by (1) presence of an HR-related mutation or (2) an increase in loss of heterozygosity (LOH) score. Results: 72 pts were enrolled, with 70 pts receiving study treatment (35 plat sensitive and 35 plat resistant). BROCA-HR analysis is complete on 60 samples, with 10 samples in final analysis. The concordance of HRD status by presence of an HR-related mutation or by LOH score was relatively low (agreement=36/60=60%, Cohen9s Kappa=0.28). In 19 pts with a germline BRCA mutation, 16 were HRD+ by LOH (LOH high), 2 were HRD- by LOH (LOH low), and 1 not quantifiable. 3 pts had a somatic BRCA mutation; 1 was LOH high, 1 LOH low, and 1 not quantifiable. 4 pts had non-BRCA somatic HR-related mutations (3 CDK12; 1 ATR); 3 were LOH high and 1 LOH low. Of the 34 pts without HR-related mutations, 15 were LOH high, 16 were LOH low, and 3 not quantifiable. In 29 plat sensitive pts with BROCA-HR results, 18 were HRD+ by mutation (12 germline BRCA, 3 somatic BRCA, 3 somatic other), and 16 were HRD+ by LOH (LOH high). The ORR in plat sensitive pts by HRD status with available HRD results was: 22/29=75.9% (13/18=72% HRDmut+; 9/11=82% HRDmut-); (12/16=75% LOH high; 6/9= 67% LOH low). In 31 plat resistant pts with BROCA-HR results, 8 were HRD+ by mutation (7 germline BRCA, 0 somatic BRCA, 1 somatic other), and 19 were HRD+ by LOH. The ORR in plat resistant pts by HRD status with available HRD results was: 7/31=22.6% (4/8=50% HRDmut+; 3/23=13% HRDmut-, P=0.05); (7/19=37% LOH high; 0/11= 0% LOH low, P=0.03). Updated results with the full data set are pending. Conclusion: Ced/olap has clinical activity in women with relapsed ovarian cancer, both in the plat sensitive and plat resistant settings. In women with plat sensitive disease, where response rates are high, HRD status by presence of an HR-related mutation or LOH status does not appear to provide significant additional information regarding likelihood of response. In women with plat resistant disease, the presence of HRD by an HR-related mutation or LOH status is correlated with a higher likelihood of response. Citation Format: Joyce F Liu, Su-Chun Cheng, Robert M Wenham, Andrea E Wahner Hendrickson, Deborah K Armstrong, Nancy Chan, David E Cohn, Jung-Min Lee, Richard T Penson, Mihaela Cristea, James Abbruzzese, Koji Matsuo, Alexander B Olawaiye, Jennifer Curtis, Geoffrey Shapiro, Ursula A Matulonis, Elise Kohn, Percy Ivy, Elizabeth M Swisher. Correlation of homologous recombination deficiency (HRD) status by BROCA-HR sequencing with response to combination cediranib and olaparib in relapsed ovarian cancer [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2019 Oct 26-30; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2019;18(12 Suppl):Abstract nr A074. doi:10.1158/1535-7163.TARG-19-A074" @default.
• W2991865732 created "2019-12-13" @default.
• W2991865732 creator A5003082405 @default.
• W2991865732 creator A5003353558 @default.
• W2991865732 creator A5005621340 @default.
• W2991865732 creator A5016505594 @default.
• W2991865732 creator A5025967071 @default.
• W2991865732 creator A5035694388 @default.
• W2991865732 creator A5042989894 @default.
• W2991865732 creator A5044655732 @default.
• W2991865732 creator A5045419282 @default.
• W2991865732 creator A5046159625 @default.
• W2991865732 creator A5058249824 @default.
• W2991865732 creator A5059711716 @default.
• W2991865732 creator A5060953135 @default.
• W2991865732 creator A5081735541 @default.
• W2991865732 creator A5084420374 @default.
• W2991865732 creator A5087376683 @default.
• W2991865732 creator A5089955620 @default.
• W2991865732 creator A5090143508 @default.
• W2991865732 creator A5090429618 @default.
• W2991865732 date "2019-12-01" @default.
• W2991865732 modified "2023-09-26" @default.
• W2991865732 title "Abstract A074: Correlation of homologous recombination deficiency (HRD) status by BROCA-HR sequencing with response to combination cediranib and olaparib in relapsed ovarian cancer" @default.
• W2991865732 doi "https://doi.org/10.1158/1535-7163.targ-19-a074" @default.
• W2991865732 hasPublicationYear "2019" @default.
• W2991865732 type Work @default.
• W2991865732 sameAs 2991865732 @default.
• W2991865732 citedByCount "0" @default.
• W2991865732 crossrefType "proceedings-article" @default.
• W2991865732 hasAuthorship W2991865732A5003082405 @default.
• W2991865732 hasAuthorship W2991865732A5003353558 @default.
• W2991865732 hasAuthorship W2991865732A5005621340 @default.
• W2991865732 hasAuthorship W2991865732A5016505594 @default.
• W2991865732 hasAuthorship W2991865732A5025967071 @default.
• W2991865732 hasAuthorship W2991865732A5035694388 @default.
• W2991865732 hasAuthorship W2991865732A5042989894 @default.
• W2991865732 hasAuthorship W2991865732A5044655732 @default.
• W2991865732 hasAuthorship W2991865732A5045419282 @default.
• W2991865732 hasAuthorship W2991865732A5046159625 @default.
• W2991865732 hasAuthorship W2991865732A5058249824 @default.
• W2991865732 hasAuthorship W2991865732A5059711716 @default.
• W2991865732 hasAuthorship W2991865732A5060953135 @default.
• W2991865732 hasAuthorship W2991865732A5081735541 @default.
• W2991865732 hasAuthorship W2991865732A5084420374 @default.
• W2991865732 hasAuthorship W2991865732A5087376683 @default.
• W2991865732 hasAuthorship W2991865732A5089955620 @default.
• W2991865732 hasAuthorship W2991865732A5090143508 @default.
• W2991865732 hasAuthorship W2991865732A5090429618 @default.
• W2991865732 hasConcept C104317684 @default.
• W2991865732 hasConcept C121608353 @default.
• W2991865732 hasConcept C126322002 @default.
• W2991865732 hasConcept C143998085 @default.
• W2991865732 hasConcept C160798450 @default.
• W2991865732 hasConcept C182979987 @default.
• W2991865732 hasConcept C2779962180 @default.
• W2991865732 hasConcept C2780427987 @default.
• W2991865732 hasConcept C2780739268 @default.
• W2991865732 hasConcept C3019894029 @default.
• W2991865732 hasConcept C55493867 @default.
• W2991865732 hasConcept C71924100 @default.
• W2991865732 hasConcept C82381507 @default.
• W2991865732 hasConcept C86803240 @default.
• W2991865732 hasConceptScore W2991865732C104317684 @default.
• W2991865732 hasConceptScore W2991865732C121608353 @default.
• W2991865732 hasConceptScore W2991865732C126322002 @default.
• W2991865732 hasConceptScore W2991865732C143998085 @default.
• W2991865732 hasConceptScore W2991865732C160798450 @default.
• W2991865732 hasConceptScore W2991865732C182979987 @default.
• W2991865732 hasConceptScore W2991865732C2779962180 @default.
• W2991865732 hasConceptScore W2991865732C2780427987 @default.
• W2991865732 hasConceptScore W2991865732C2780739268 @default.
• W2991865732 hasConceptScore W2991865732C3019894029 @default.
• W2991865732 hasConceptScore W2991865732C55493867 @default.
• W2991865732 hasConceptScore W2991865732C71924100 @default.
• W2991865732 hasConceptScore W2991865732C82381507 @default.
• W2991865732 hasConceptScore W2991865732C86803240 @default.
• W2991865732 hasLocation W29918657321 @default.
• W2991865732 hasOpenAccess W2991865732 @default.
• W2991865732 hasPrimaryLocation W29918657321 @default.
• W2991865732 hasRelatedWork W12581806 @default.
• W2991865732 hasRelatedWork W15143329 @default.
• W2991865732 hasRelatedWork W17587699 @default.
• W2991865732 hasRelatedWork W2544042 @default.
• W2991865732 hasRelatedWork W2855694 @default.
• W2991865732 hasRelatedWork W2976006 @default.
• W2991865732 hasRelatedWork W3184125 @default.
• W2991865732 hasRelatedWork W3251518 @default.
• W2991865732 hasRelatedWork W7720014 @default.
• W2991865732 hasRelatedWork W8036688 @default.
• W2991865732 isParatext "false" @default.
• W2991865732 isRetracted "false" @default.
• W2991865732 magId "2991865732" @default.
• W2991865732 workType "article" @default.